Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient's quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant prostate cancer) patients with symptomatic bone metastases. To our knowledge, no previous study has been performed assessing the bone pain palliation outcomes following Radium-223 therapy.
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC / Frantellizzi, Viviana; Lazri, Julia; Pontico, Mariano; Pani, Arianna; De Vincentis, Giuseppe. - In: ARCHIVIO ITALIANO DI UROLOGIA ANDROLOGIA. - ISSN 2282-4197. - 92:3(2020), pp. 1-4. [10.4081/aiua.2020.3.196]
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
Frantellizzi, VivianaPrimo
;Lazri, JuliaSecondo
;Pontico, Mariano;De Vincentis, GiuseppeUltimo
2020
Abstract
Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient's quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant prostate cancer) patients with symptomatic bone metastases. To our knowledge, no previous study has been performed assessing the bone pain palliation outcomes following Radium-223 therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Frantellizzi_Bone-pain_2020.pdf
accesso aperto
Note: https://pagepressjournals.org/index.php/aiua/article/view/aiua.2020.3.196
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
434.37 kB
Formato
Adobe PDF
|
434.37 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
